<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29036" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Simvastatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Talreja</surname>
            <given-names>Om</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerndt</surname>
            <given-names>Connor C.</given-names>
          </name>
          <aff>Spectrum Health/Michigan State University College of Human Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Om Talreja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Connor Kerndt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29036.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet. It is a semi-synthetic derivative of lovastatin, the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke. However, there are several more effective statins with more favorable adverse effect profiles. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, and monitoring, of simvastatin, so providers can direct patient therapy in treating hyperlipidemia as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of simvastatin.</p></list-item><list-item><p>Review the indications for using simvastatin in lipid control.</p></list-item><list-item><p>Explain the adverse event profile of simvastatin and how it compares with other statin medications.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to examine simvastatin use and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29036&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29036">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29036.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Simvastatin is an oral HMG-CoA reductase inhibitor indicated as an adjunct to diet, exercise, weight loss, and possibly other medications as&#x000a0;part&#x000a0;of an overall lipid-lowering and cardiovascular&#x000a0;health regimen. It is a semi-synthetic derivative of lovastatin,&#x000a0;the first FDA-approved statin. Simvastatin helps lower cholesterol production and reduce dyslipidemia-associated complications. High concentrations of LDL cholesterol can lead to artery damage, potentially leading to cardiac complications and stroke.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Homozygous/heterozygous familial hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Heterozygous NonFamilial hypercholesterolemia</p>
          </list-item>
          <list-item>
            <p>Hypertriglyceridemia</p>
          </list-item>
          <list-item>
            <p>Dysbetalipoproteinemia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Reduction of adverse cardiovascular events&#x000a0;</p>
          </list-item>
        </list>
        <p>Simvastatin is also used off-label for prophylactic and therapeutic indications.</p>
        <p>
<bold>Non-FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prophylaxis of adverse cardiovascular outcomes post-acute-coronary-syndrome hospitalization&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prophylaxis of atrial fibrillation among patients with stable coronary artery disease</p>
          </list-item>
        </list>
        <p>Simvastatin is&#x000a0;used as monotherapy and is available in combination products to treat dyslipidemia. Combination products include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Simvastatin/ezetimibe<xref ref-type="bibr" rid="article-29036.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Simvastatin/niacin extended-release (ER)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29036.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Clinicians prescribe statin therapy to lower cholesterol concentrations; simvastatin targets cholesterol production. The biosynthesis of this molecule consists of a multi-step pathway. The rate-limiting step in this pathway involves the 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase enzyme. Using acetyl-CoA as a substrate, mevalonic acid is formed, and subsequent reactions lead to the formation of cholesterol. Simvastatin acts on the rate-limiting step and serves as an HMG-CoA reductase inhibitor, consequently leading to decreased cholesterol concentrations.</p>
        <p>Statins also possess additional properties in addition to their ability to lower cholesterol concentrations. These include inhibition of platelet aggregation, reduction in inflammation at the site of atherosclerotic plaque, and improved endothelial function. These properties are commonly taken advantage of when prescribing statin therapy for&#x000a0;individuals with normal cholesterol levels. Studies have shown that early statin therapy initiation has&#x000a0;reduced the incidence of cardiovascular events, leading to reduced mortality.<xref ref-type="bibr" rid="article-29036.r2">[2]</xref></p>
        <p>Simvastatin is hepatically metabolized via the CYP450 enzyme system, primarily through CYP3A4 as well as CYP2C6; this figures prominently in some of its potential adverse effects and drug-drug interactions, of which more later. It is a prodrug. It is excreted in the feces and urine and has a half-life of between two and five hours.</p>
      </sec>
      <sec id="article-29036.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Simvastatin is approved for oral administration and is available in 5-mg, 10-mg, 20-mg, 40-mg, and 80-mg tablets. A suspension dosage form is also available for those with difficulty swallowing.</p>
        <p>
<bold>Recommended Dosages*</bold>
</p>
        <p>
<bold>Homozygous Familial Hypercholesterolemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>40 mg once every evening</p>
          </list-item>
        </list>
        <p>
<bold>Heterozygous Familial Hypercholesterolemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial 10 to 20 mg once every evening; max dose 40 mg once every evening</p>
          </list-item>
          <list-item>
            <p>Pediatric patients age 10 to 17: Initial 10 mg once every evening;&#x000a0;max dose 40 mg once every evening</p>
          </list-item>
        </list>
        <p>
<bold>Hypertriglyceridemia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial 10 to 20 mg once every evening; max dose 40 mg once every evening</p>
          </list-item>
        </list>
        <p>
<bold>Reduction in Cardiovascular Events</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Initial 10 to 20 mg once every evening; max dose 40 mg once every evening</p>
          </list-item>
          <list-item>
            <p>In patients with coronary heart disease (CHD), the initial dose is 40 mg once every evening</p>
          </list-item>
        </list>
        <p>A dose restriction exists for simvastatin 80 mg due to a higher risk of myopathy and possible&#x000a0;rhabdomyolysis, especially within the first 12 months of use. Therefore, the 80-mg strength is restricted&#x000a0;for only those patients who have been on the 80-mg regimen for 12 or more months with no reported myopathy. Simvastatin 80 mg is not recommended for patients with LDL targets that&#x000a0;are not at goal, even with simvastatin 40 mg. Recommendations are to use a high-intensity statin instead. For stable patients on the simvastatin 80-mg dose, a change of therapy&#x000a0;is necessary if initiating an interacting medication.</p>
        <p>*Doses are adjusted to target goal LDL levels.</p>
        <p>
<bold>Dose Adjustments</bold>
</p>
        <p>Dose adjustments are necessary with simvastatin when taken concomitantly with certain pharmacotherapy. Adjustments in simvastatin strength reduce potential statin-associated toxicities, including fatigue and myopathy.</p>
        <p>Potent CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors, cyclosporine)</p>
        <list list-type="bullet">
          <list-item>
            <p>Simvastatin is contraindicated:
<list list-type="bullet"><list-item><p>Verapamil, diltiazem, dronedarone
<list list-type="bullet"><list-item><p>Max dose is simvastatin 10 mg</p></list-item></list>
</p></list-item><list-item><p>Amiodarone, amlodipine, ranolazine
<list list-type="bullet"><list-item><p>Max dose is simvastatin 20 mg</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29036.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Common adverse effects include headaches, myalgia, abdominal pain, gastritis, constipation, upper respiratory infections, elevated AST or ALT, and impaired serum glucose control.<xref ref-type="bibr" rid="article-29036.r3">[3]</xref></p>
        <p>Rarer, yet more severe, causations&#x000a0;include cardiovascular effects such as atrial fibrillation,&#x000a0;hepatic abnormalities, including cholestatic hepatitis, greater than a 3-fold elevation in transaminases, jaundice, and potential liver failure. Adverse musculoskeletal effects include greater than a three-fold increase in creatine phosphokinase (CPK) levels, rhabdomyolysis, and compartment syndrome in the lower legs.<xref ref-type="bibr" rid="article-29036.r4">[4]</xref><xref ref-type="bibr" rid="article-29036.r5">[5]</xref><xref ref-type="bibr" rid="article-29036.r6">[6]</xref></p>
        <p>Additional serious reactions include interstitial lung disease, diabetes mellitus, erythema multiforme, leukopenia, hemolytic anemia, thrombocytopenia, and Stevens-Johnson syndrome, although these adverse events are rare.&#x000a0;</p>
        <p>Drug concentrations, and consequently, incidence and severity of adverse effects, can become&#x000a0;significantly increased&#x000a0;when coadministered with CYP3A4 inhibitors. Concomitant medications administered with simvastatin should have an assessment performed for potential drug interactions to minimize the risk of adverse effects. Patients are commonly advised to stop eating grapefruits or drinking grapefruit juice while on statin therapy. However, more recent research has shown this risk can be minimized by spacing the consumption of grapefruit and statin dosing.<xref ref-type="bibr" rid="article-29036.r7">[7]</xref></p>
      </sec>
      <sec id="article-29036.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with contraindications to simvastatin pharmacotherapy include those&#x000a0;with active liver disease, including those who have elevated hepatic enzymes, pregnancy, and women who may become pregnant or who are breastfeeding. Concomitant use with certain medications (see above) is also a contraindication with simvastatin, and drug profiles should&#x000a0;undergo&#x000a0;a careful review prior to&#x000a0;initiation.</p>
        <p>Pregnancy is a known secondary cause of dyslipidemia, leading to a potential increase in triglyceride and LDL-C concentrations. Statin therapy is contraindicated during pregnancy resulting in limited options for dyslipidemia treatment during pregnancy. Alternative treatment options are necessary&#x000a0;to treat elevated concentrations during pregnancy to minimize associated complications such as hypertriglyceridemia related to acute pancreatitis. Pregnancy has been delayed or avoided in reported cases to avoid the possible&#x000a0;complications from untreated dyslipidemia.<xref ref-type="bibr" rid="article-29036.r8">[8]</xref>&#x000a0;Females of child-bearing potential are advised to use appropriate contraception during treatment with simvastatin. Recommendations are also to avoid breastfeeding if possible; if unavoidable, clinicians need to weigh potential benefits vs. risk profile, although there is no current data on infant harm or adverse effects on breast milk production.<xref ref-type="bibr" rid="article-29036.r9">[9]</xref></p>
        <p>Although rare, a serious complication of statin therapy is liver toxicity with elevated levels of transaminases. Due to a&#x000a0;potential increase in liver enzymes, patients with active liver disease and pre-existing elevated transaminases are excluded from simvastatin therapy. Simvastatin can transiently increase transaminase concentrations within the first few months of treatment. These&#x000a0;subsequently return&#x000a0;to baseline. The clinician should monitor liver function and enzymes&#x000a0;while their patients are on simvastatin pharmacotherapy.<xref ref-type="bibr" rid="article-29036.r10">[10]</xref></p>
        <p>Contraindicated drugs for concomitant use with simvastatin include atazanavir, chloramphenicol, erythromycin, gemfibrozil, ritonavir, and azole antifungals. This is not an exhaustive list, and complete medication reconciliation is recommended, as with any drug regimen.<xref ref-type="bibr" rid="article-29036.r11">[11]</xref></p>
      </sec>
      <sec id="article-29036.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Continuous laboratory monitoring is not necessary for patients on simvastatin therapy. To gauge therapeutic effectiveness, a lipid profile&#x000a0;is evaluated four weeks after initiation and periodically after that leading to potential dose adjustments. Liver function tests are also performed at baseline and subsequently, as clinically necessitated, to evaluate&#x000a0;liver toxicities. Common symptoms include abdominal pain, yellowing of the skin, loss of appetite, and fatigue.&#x000a0;Creatine kinase levels are also assessed at baseline and periodically after that, especially in high-risk patients such as those with renal insufficiency. Patients with complex medication profiles (polypharmacy) require close monitoring for musculoskeletal and hepatic complaints due to potential simvastatin toxicities and possible drug-drug interactions.<xref ref-type="bibr" rid="article-29036.r12">[12]</xref></p>
      </sec>
      <sec id="article-29036.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Severe cases of musculoskeletal symptoms warrant discontinuation of simvastatin. In milder cases, the currently accepted practice is temporary discontinuation followed by a re-challenge at a lower dose. If re-challenging simvastatin at a lower dose leads to similar adverse effects, discontinuation followed by an alternative statin is the recommended next step.<xref ref-type="bibr" rid="article-29036.r13">[13]</xref>&#x000a0;Discontinuation&#x000a0;is also warranted if severe hepatotoxicity or hyperbilirubinemia or if jaundice occurs.</p>
      </sec>
      <sec id="article-29036.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Simvastatin has&#x000a0;been used for many years to treat dyslipidemia and high-risk patients such as people with diabetes. Common clinical pearls can help limit potential adverse effects and enhance patient outcomes.</p>
        <list list-type="bullet">
          <list-item>
            <p>Due to an increased risk of myopathy, the 80-mg dose&#x000a0;is restricted to patients who have been stable on 80 mg for at least 12 months. If additional LDL-lowering&#x000a0;is required, switch to a high-intensity statin.</p>
          </list-item>
          <list-item>
            <p>Use a lower starting dose and monitor for patients who&#x000a0;are of Chinese descent.<xref ref-type="bibr" rid="article-29036.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Use further caution in patients who are chronic alcohol consumers and/or have a history of liver disease.</p>
          </list-item>
          <list-item>
            <p>Avoid the consumption of grapefruit juice, or space the consumption of grapefruit and grapefruit juice from statin dosing.<xref ref-type="bibr" rid="article-29036.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>Simvastatin therapy can address dyslipidemia in those patients with such a profile. However, newer statin agents with fewer interactions and adverse effects have replaced&#x000a0;simvastatin as the first-line agent for statin therapy. Currently, it is more common to initiate treatment on these newer agents, leaving simvastatin for those who have had successful results using the drug with no adverse events. For those patients who receive dyslipidemia therapy with simvastatin, the interprofessional healthcare team, consisting of clinicians (MDs, DOs, NPS, and PAs), specialists, nurses, and pharmacists, should work together to monitor for therapeutic results and adverse effects and the pharmacist can suggest equivalent dosing with other statins less prone to adverse events.</p>
        <p>When the clinician prescribes simvastatin, the nursing staff should review dosing and administration with the patient and answer patient questions about their medication therapy. It is incumbent on the pharmacist to perform medication reconciliation and verify that there are no potential drug-drug interactions that need to be addressed and that the dosing of the drug is appropriate. Any concerns should be reported to the prescriber or nursing staff, so appropriate measures can be taken to alter the patient's therapy.<xref ref-type="bibr" rid="article-29036.r15">[15]</xref> All interprofessional team members should be vigilant for adverse events and immediately report them to the rest of the team. This interprofessional approach can drive better patient outcomes with fewer side effects. [Level 5]</p>
      </sec>
      <sec id="article-29036.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29036&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29036">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29036/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29036">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29036.s11">
        <title>References</title>
        <ref id="article-29036.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gryn</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Ezetimibe plus simvastatin for the treatment of hypercholesterolemia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>1255</fpage>
            <page-range>1255-62</page-range>
            <pub-id pub-id-type="pmid">25920750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Denus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spinler</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Early statin therapy for acute coronary syndromes.</article-title>
            <source>Ann Pharmacother</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>1749</fpage>
            <page-range>1749-58</page-range>
            <pub-id pub-id-type="pmid">12398573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trias</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pint&#x000f3;</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Corbella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Tembra</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ru&#x000ed;z-Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D&#x000ed;az-D&#x000ed;az</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Ru&#x000ed;z-Granado</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sarasa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Porqueras</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-S&#x000e1;nchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Corbella</surname>
                <given-names>X</given-names>
              </name>
              <collab>PRELIPID Study Group</collab>
            </person-group>
            <article-title>Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID study.</article-title>
            <source>Med Clin (Barc)</source>
            <year>2022</year>
            <month>Jun</month>
            <day>10</day>
            <volume>158</volume>
            <issue>11</issue>
            <fpage>531</fpage>
            <page-range>531-539</page-range>
            <pub-id pub-id-type="pmid">34517987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chochola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lubanda</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Skalicka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Varejka</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Horejs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Prskavec</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bal&#x000ed;k</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Semr&#x000e1;d</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linhart</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Bilateral leg compartment syndrome due to severe myonecrosis caused by inappropriate use of simvastatin].</article-title>
            <source>J Mal Vasc</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>4-5</issue>
            <fpage>229</fpage>
            <page-range>229-33</page-range>
            <pub-id pub-id-type="pmid">18819764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parkin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herbison</surname>
                <given-names>GP</given-names>
              </name>
            </person-group>
            <article-title>Simvastatin dose and risk of rhabdomyolysis: nested case-control study based on national health and drug dispensing data.</article-title>
            <source>Int J Cardiol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>01</day>
            <volume>174</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-9</page-range>
            <pub-id pub-id-type="pmid">24726164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Somagutta</surname>
                <given-names>MKR</given-names>
              </name>
              <name>
                <surname>Shama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pormento</surname>
                <given-names>MKL</given-names>
              </name>
              <name>
                <surname>Jagani</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ngardig</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Ghazarian</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahmutaj</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>El-Faramawy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahadevaiah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Statin-induced necrotizing autoimmune myopathy: a systematic review.</article-title>
            <source>Reumatologia</source>
            <year>2022</year>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-69</page-range>
            <pub-id pub-id-type="pmid">35645423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Wald</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Grapefruit Juice and Statins.</article-title>
            <source>Am J Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>129</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-9</page-range>
            <pub-id pub-id-type="pmid">26299317</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Severe dyslipidemia in pregnancy: The role of therapeutic apheresis.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>283</fpage>
            <page-range>283-7</page-range>
            <pub-id pub-id-type="pmid">26626968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <article-title>Comparison table: Some lipid-lowering drugs.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2019</year>
            <month>Feb</month>
            <day>11</day>
            <volume>61</volume>
            <issue>1565</issue>
            <fpage>e24</fpage>
            <page-range>e24-e30</page-range>
            <pub-id pub-id-type="pmid">30845107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calderon</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Cubeddu</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Schiff</surname>
                <given-names>ER</given-names>
              </name>
            </person-group>
            <article-title>Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>349</fpage>
            <page-range>349-56</page-range>
            <pub-id pub-id-type="pmid">20360293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laufs</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Weing&#x000e4;rtner</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kassner</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schatz</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>[State of the Art: Statin Therapy].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>147</volume>
            <issue>1-02</issue>
            <fpage>62</fpage>
            <page-range>62-68</page-range>
            <pub-id pub-id-type="pmid">34872149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.</article-title>
            <source>Intern Med J</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>44</volume>
            <issue>7</issue>
            <fpage>690</fpage>
            <page-range>690-3</page-range>
            <pub-id pub-id-type="pmid">25041770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Panza</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms.</article-title>
            <source>Int J Cardiol</source>
            <year>2016</year>
            <month>Apr</month>
            <day>15</day>
            <volume>209</volume>
            <fpage>12</fpage>
            <page-range>12-3</page-range>
            <pub-id pub-id-type="pmid">26874453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Safety and efficacy of statins in Asians.</article-title>
            <source>Am J Cardiol</source>
            <year>2007</year>
            <month>Feb</month>
            <day>01</day>
            <volume>99</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-4</page-range>
            <pub-id pub-id-type="pmid">17261409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29036.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamadouk</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Albashair</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Yousef</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>The Practice of the Community Pharmacists in Managing Potential Drug-Drug Interactions: A Simulated Patient Visits.</article-title>
            <source>Integr Pharm Res Pract</source>
            <year>2022</year>
            <volume>11</volume>
            <fpage>71</fpage>
            <page-range>71-84</page-range>
            <pub-id pub-id-type="pmid">35313632</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
